NewAmsterdam Pharma Initiates P-II Dose-Finding Study of Obicetrapib for the Treatment of Dyslipidemia
Shots:
- The company initiates a P-II study evaluating the efficacy, safety & tolerability of obicetrapib as an adjunct to stable statin therapy in 108 Japanese patients with dyslipidemia. The results are expected in H2’23
- The company assumed that adding obicetrapib to statin therapy will reduce levels of LDL-C. Obicetrapib is being studied in 3 P-III trials i.e., (BROADWAY) for ASCVD and or HeFH, (BROOKLYN) for HeFH & (PREVAIL) CVOT in patients with ASCVD & LDL-C ≥ 70 mg/dL)
- The therapy is also being evaluated in a secondary P-II (ROSE2) in combination with ezetimibe for high-intensity statin therapy. Obicetrapib is an oral, low-dose & CETP inhibitor currently in development for CV disease as monothx. and in a fixed-dose combination with ezetimibe
Ref: Businesswire | Image: NewAmsterdam Pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
